New research shows how using molecular tools and alternative gene splicing can make a protein called CEACAM1 more protective against liver injury during transplantation, thus reducing organ injury and ultimately improving post-transplant outcomes.
Cancer research centers conducting clinical trials could enroll more patients from underrepresented racial and ethnic groups by placing greater emphasis on relieving investigators of the costs of translating consent documents into languages other than English, according to a UCLA Jonsson Comprehensive Cancer Center study.
Therapy animals are bringing their own version of Taylor Swift’s blockbuster Eras Tour to hospitalized children in a glamorous parade and fashion show of her famous tour costumes! After the show, they – and their handlers – will go up to the unit to visit the patients, spreading good cheer and licensed tour merchandise and friendship bracelets.
UCLA Health researchers have published the largest-ever study of families with at least two children with autism, uncovering new risk genes and providing new insights into how genetics influence whether someone develops autism spectrum disorder.
A new study from UCLA Health researchers finds that the typical ways health systems store and track data on children receiving emergency care miss a sizable portion of those who are having self-injurious thoughts or behaviors. The researchers also found that several machine learning models they designed were significantly better at identifying those children at risk of self-harm.
Kundalini yoga, a form of yoga that focuses on breathing, meditation, and mental visualization, appeared beneficial for older women who had risk factors for Alzheimer’s disease and concerns about episodes of memory decline, according to a UCLA Health study.
A molecular imaging tool developed by researchers at UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer recurrence in patients with intermediate to high-risk prostate cancer who undergo surgery.
A new study, which involved experiments on mice and human patients, uncovered an important communication pathway between two molecules called CEACAM1 (CC1) and TIM-3, finding that the pathway plays a crucial role in controlling the body's immune response during liver transplantation.
The research underscores the limitations of the health care system’s frequent reliance on broad self-reported race and ethnicity data to assess patients’ risk of developing disease, and the findings also support expanding genetic screening to more groups.
Study suggests modulating the activity of certain neurons could be an effective approach to restoring circuit function.
New research suggests that targeting autoimmune inflammation associated with amyotrophic lateral sclerosis (ALS) using two drugs, one of them already approved for multiple sclerosis, could be a promising approach for treatment.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have confirmed that a large number of genetic variants of unknown significance are in fact verified mutations that predispose patients to a rare hereditary syndrome that increases the risk of kidney cancer.
UCLA Health dermatologist Caroline Opene, MD treats patients of all skin tones, but as director of the UCLA Health Skin of Color clinic, she has special expertise in treating skin of color.
A UCLA-led team has received $925,000 as part of a new grant from the Centers for Disease Control and Prevention (CDC) to conduct four surveillance projects tracking outbreaks of mpox--formerly known as monkeypox—across the U.S.
A new study shows that an artificial intelligence (AI) model co-developed by researchers in the UCLA Jonsson Comprehensive Cancer Center and department of Urology at UCLA can help doctors determine the extent of cancer within the prostate.
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified potential new biomarkers that could indicate how someone diagnosed with metastatic melanoma will respond to immunotherapy treatment.
Patients with congestive heart failure experiencing shortness of breath are less likely to be tested in the emergency department for a potentially fatal pulmonary embolism when the reason for the visit is initially noted as congestive heart failure instead of the broader “shortness of breath”.
Monthly cash payments to eligible families under the temporary pandemic-era expansion of the federal Child Tax Credit led to better adult health and food security, new UCLA-led research suggests.
UCLA Health is now accepting applications for a new cohort of innovators to be part of its TechQuity Accelerator for 2023, an initiative that supports startups and other fledgling companies with technologies that can improve health equity among underserved and vulnerable patient populations.
There are few effective treatments for acute stroke, and many patients aren’t eligible for them. An innovative pilot study from UCLA Health found promising results for a new potential treatment: highly targeted electrical stimulation to the affected brain area.
A statewide pay-for-performance intervention based on a set of guidelines called Choosing Wisely reduced rates of inappropriate antibiotic prescriptions to treat acute respiratory tract infections by an average of 18 percentage points, from 43% to 25%, across two large Los Angeles safety net hospitals.
Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a new method to bioprint miniature tumor organoids that are designed to mimic the function and architecture of real tumors. The improved process allows researchers to use an advanced imaging method to study and analyze individual organoids in great detail, which can help researchers identify personalized treatments for people with rare or hard-to-treat cancers.
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
A study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are significant survival benefits for patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.
A brief roundup of news and story ideas from the experts at UCLA Health. For more information on these stories or for help on other stories, please contact us at [email protected].
This study provides provides the first physiological evidence from inside the human brain supporting the dominant scientific theory on how the brain consolidates memory during sleep. Further, deep-brain stimulation during a critical time in the sleep cycle appeared to improve memory consolidation.
New UCLA-led research suggests that patient mortality rates, readmissions, length of stay, and health care spending were virtually identical for elderly hospitalized patients who were treated by physicians with Doctor of Medicine (MD) or Doctor of Osteopathic Medicine (DO) degrees.
The discovery suggests that one possible approach to treat glioblastoma would be a therapy that targets the metabolic process in patients who have that genetic alteration.
The commonly used U.S version of the Fracture Risk Assessment Tool (FRAX) should not be routinely used to select younger postmenopausal women for bone mineral density testing. But the Osteoporosis Self-Assessment Tool (OST) is excellent at identifying women with osteoporosis-level bone mineral density, which is the goal of these screenings, while FRAX is not.
Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology’s annual meeting.
Polygenic scores – estimates of an individual’s predisposition for complex traits and diseases – hold promise for identifying patients at risk of disease and guiding early, personalized treatments, but UCLA experts found the scores fail to account for the wide range of genetic diversity across individuals in all ancestries.
Through a novel pairing of epidemiology and toxicity screening, UCLA and Harvard researchers were able to identify 10 pesticides that were directly toxic to key neurons.
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center suggests that IL-21, a soluble molecule involved in activating the immune system, can be a potential therapeutic target to help reduce endocrine autoimmune side effects caused by checkpoint inhibitor cancer therapy.
The anti-dementia medication lecanemab and its ancillary costs could add $2 billion to $5 billion in annual Medicare spending if the Centers for Medicare and Medicaid Services (CMS) revise their coverage decision. Currently, the medication is covered only for patients who are enrolled in clinical trials.
UCLA researchers have developed an “all-in-one,” next-generation statistical simulator capable of assimilating a wide range of information to generate realistic synthetic data and provide a benchmarking tool for medical and biological researchers who use advanced technologies to study diseases and potential therapies.
Researchers have developed a zebrafish model that provides new insight into how the brain acquires essential omega-3 fatty acids, including docosahexaenoic acid (DHA) and linolenic acid (ALA), creating the potential to improve understanding of lipid transport across the blood-brain barrier.
A sharp increase in the price of the gout drug colchicine, the result of an unusual FDA policy, led to lower use and poorer disease control. The findings have implications for other drugs, whose price could be similarly affected by government policies and manufacturer decisions.
People who perceived that they had cognitive difficulties such as memory problems during COVID were more likely to have lingering physical manifestations of the disease than people who did not report cognitive issues.
Ten nurses from UCLA Health are among 30 honored by the Simms/Mann Family Foundation in a generous program to recognize the mettle of nurses in Los Angeles. The program, Off the Chart: Rewarding Nursing Greatness, Powered by the Simms/Mann Family Foundation, recognized 30 nurses working at three medical centers in the region.
The California Center for Rare Diseases at UCLA has been designated as a NORD Rare Disease Center of Excellence, becoming one of 40 U.S. academic medical centers selected to be a part of the first-of-it-kind national network of U.S. medical institutions dedicated to diagnosing, treating, and researching all rare diseases.
Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center and the Department of Urology at the David Geffen School of Medicine at UCLA will be joining thousands of urology experts on April 28 to May 1 for the American Urological Association (AUA) Annual Meeting.
In a new translational study from UCLA Jonsson Comprehensive Cancer Center, researchers analyzed genetic changes in the organs of recently deceased patients to understand how metastatic cutaneous melanoma spreads in those who had initially benefited from precision therapies.
Physician scientists from the UCLA Department of Pediatrics at the David Geffen School of Medicine at UCLA will present on the latest scientific advancements at the Pediatric Academic Societies (PAS) annual meeting April 27-May 1, 2023 in Washington, D.C.
UCLA Health investigators are leading a new, six-city trial of injectable buprenorphine for treatment of methamphetamine use disorder in adults who also use opioids.
New UCLA research suggests that a novel machine-learning technique known as "causal forest" was about five times more efficient than the current clinical practice of treating patients with high blood pressure.
A type of cell usually characterized as the brain’s support system appears to play an important role in OCD, providing a surprising new clue about potential therapeutic strategies for the disorder.
Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy – CTLA-4 blockade – as well as other factors.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right